实用医学杂志
實用醫學雜誌
실용의학잡지
The Journal of Practical Medicine
2015年
16期
2637-2640
,共4页
麦林琳%胡允兆%吴焱贤%欧阳海春%陈盈文%王航鹰
麥林琳%鬍允兆%吳焱賢%歐暘海春%陳盈文%王航鷹
맥림림%호윤조%오염현%구양해춘%진영문%왕항응
心房颤动%冠状动脉疾病%血管成形术,经腔,经皮冠状动脉%华法林%血小板聚集抑制剂
心房顫動%冠狀動脈疾病%血管成形術,經腔,經皮冠狀動脈%華法林%血小闆聚集抑製劑
심방전동%관상동맥질병%혈관성형술,경강,경피관상동맥%화법림%혈소판취집억제제
Atrial fibrillation%Coronary disease%Angioplasty%transluminal%percutaneous coronary%Warfarin%Platelet aggregation inhibitors
目的:比较心房颤动合并经皮冠状动脉介入治疗(PCI)术后采用二联抗栓方案(华法林+氯吡格雷)(DT)和3 个月的三联抗栓方案(华法林+阿司匹林+氯吡格雷)(TT)+9 个月的二联抗栓方案(华法林+氯吡格雷,DT)(TT+DT)的有效性和安全性. 方法:入选心房颤动合并 PCI 术后病例 90 例,随机分为DT组(45例)和TT+DT组(45例). DT组采用12个月的二联抗栓方案,TT+DT组采用3个月的三联抗栓+9个月的二联抗栓方案. 对两组的有效性及安全性进行随访. 结果:有效性随访结果表明:TT+DT组心肌梗死、靶血管血运重建、卒中及支架内血栓形成事件低于 DT 组(P<0.05). 安全性随访结果表明:TT+DT组出血事件高于DT组,但无统计学差异(P>0.05). 结论:心房颤动合并PCI 术后采用TT+DT方案和DT方案在出血事件的安全性方面无显著差异,但TT+DT方案组治疗有效性优于DT方案组.
目的:比較心房顫動閤併經皮冠狀動脈介入治療(PCI)術後採用二聯抗栓方案(華法林+氯吡格雷)(DT)和3 箇月的三聯抗栓方案(華法林+阿司匹林+氯吡格雷)(TT)+9 箇月的二聯抗栓方案(華法林+氯吡格雷,DT)(TT+DT)的有效性和安全性. 方法:入選心房顫動閤併 PCI 術後病例 90 例,隨機分為DT組(45例)和TT+DT組(45例). DT組採用12箇月的二聯抗栓方案,TT+DT組採用3箇月的三聯抗栓+9箇月的二聯抗栓方案. 對兩組的有效性及安全性進行隨訪. 結果:有效性隨訪結果錶明:TT+DT組心肌梗死、靶血管血運重建、卒中及支架內血栓形成事件低于 DT 組(P<0.05). 安全性隨訪結果錶明:TT+DT組齣血事件高于DT組,但無統計學差異(P>0.05). 結論:心房顫動閤併PCI 術後採用TT+DT方案和DT方案在齣血事件的安全性方麵無顯著差異,但TT+DT方案組治療有效性優于DT方案組.
목적:비교심방전동합병경피관상동맥개입치료(PCI)술후채용이련항전방안(화법림+록필격뢰)(DT)화3 개월적삼련항전방안(화법림+아사필림+록필격뢰)(TT)+9 개월적이련항전방안(화법림+록필격뢰,DT)(TT+DT)적유효성화안전성. 방법:입선심방전동합병 PCI 술후병례 90 례,수궤분위DT조(45례)화TT+DT조(45례). DT조채용12개월적이련항전방안,TT+DT조채용3개월적삼련항전+9개월적이련항전방안. 대량조적유효성급안전성진행수방. 결과:유효성수방결과표명:TT+DT조심기경사、파혈관혈운중건、졸중급지가내혈전형성사건저우 DT 조(P<0.05). 안전성수방결과표명:TT+DT조출혈사건고우DT조,단무통계학차이(P>0.05). 결론:심방전동합병PCI 술후채용TT+DT방안화DT방안재출혈사건적안전성방면무현저차이,단TT+DT방안조치료유효성우우DT방안조.
Objective To compare the efficacy and safety of singular double antithrombotie therapy (DT) using warfarin plus clopidogrel and the combined antithrombotie therapy of 3-month triple antithrombotie therapy (TT) using warfarin, aspirinand clopidogrel and 9-month double antithrombotie therapy (DT) for the patients with atrial fibrillation undergoing PCI. Methods Ninety patients with atrial fibrillation undergoing PCI were randomly divided into two groups evenly: one group was treated with dual antithrombotic therapy group (DT) and the other group with the combined therapy, e. g. 3-month triple antithrombotie therapy (TT) and 9-month double antithrombotie therapy (DT + TT for short). All patients were followed-up by 12 months. The two groups were compared in terms of incidences of death , myocardial infarction , stroke , target-vessel revascularisation , stent thrombosis and bleeding adverse events. Results The incidences of myocardial infarction, stroke, target-vessel revascularisation , stent thrombosis and bleeding adverse events in the TT + DT group were all significantly lower than the DT group (P < 0.05). The follow-up on the safety indicated that the rate of bleeding in the TT +DT group was insignificantly higher than the DT group (P > 0.05). Conclusion There is no significant difference in safety between the two groups. However, the therapy of TT + DT is more effective.